The Attractiveness of PLI to Big Pharma in 3 Ways: PPPS: a process to capture new and valuable proteins from plasma for medical use in the treatment of illness/disease, proteins that are currently unattainable and lost in the Cohen process. The cost per processed liter of plasma using PPPS is much less than the current Cohen process. PPPS will revolutionize the plasma processing industry as being far more efficient and financially beneficial to a company’s bottom line.
Ryplazim: currently an estimated $8 billion USD market with no competition in the foreseeable future. Prometic will own the plasminogen market for many years thus firmly establishing themselves as the “go to” company for all patient’s plasminogen needs.
PBI-4050: 52+ weeks of data from Alstrom Syndrome patients indicates 4050 reduces fibrosis in five major organs (lung, heart, liver, kidney, pancreas) a medical claim no other drug can currently make; 4050 will be first to market with their fibrosis reduction claim and thus solidify themselves in the minds of doctors, patients, and the marketplace. Data from the 4050 trials also indicates the longer you take 4050 the better the results become. Prometic plans to increase the 800mg dosage to 1200mg in the upcoming phase 3 IPF trial for possibly even better patient results. 4050 is safe to use with no serious adverse patient events reported to date.